- Home
- ICG vs VNDA Comparison
ICG vs VNDA Comparison
Compare ICG & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICG
- VNDA
- Stock Information
- Founded
- ICG 2017
- VNDA 2002
- Country
- ICG China
- VNDA United States
- Employees
- ICG N/A
- VNDA N/A
- Industry
- ICG Semiconductors
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- ICG Technology
- VNDA Health Care
- Exchange
- ICG Nasdaq
- VNDA Nasdaq
- Market Cap
- ICG 230.3M
- VNDA 237.9M
- IPO Year
- ICG 2023
- VNDA 2006
- Fundamental
- Price
- ICG $1.93
- VNDA $4.25
- Analyst Decision
- ICG Strong Buy
- VNDA Strong Buy
- Analyst Count
- ICG 2
- VNDA 2
- Target Price
- ICG $9.50
- VNDA $16.50
- AVG Volume (30 Days)
- ICG 32.3K
- VNDA 707.5K
- Earning Date
- ICG 05-15-2025
- VNDA 05-07-2025
- Dividend Yield
- ICG N/A
- VNDA N/A
- EPS Growth
- ICG N/A
- VNDA N/A
- EPS
- ICG 0.12
- VNDA N/A
- Revenue
- ICG $38,602,978.00
- VNDA $198,772,000.00
- Revenue This Year
- ICG N/A
- VNDA $14.36
- Revenue Next Year
- ICG $603.22
- VNDA $44.53
- P/E Ratio
- ICG $15.21
- VNDA N/A
- Revenue Growth
- ICG 242.68
- VNDA 3.18
- 52 Week Low
- ICG $1.40
- VNDA $3.85
- 52 Week High
- ICG $12.04
- VNDA $6.75
- Technical
- Relative Strength Index (RSI)
- ICG 40.39
- VNDA 41.22
- Support Level
- ICG $1.40
- VNDA $4.21
- Resistance Level
- ICG $1.99
- VNDA $4.49
- Average True Range (ATR)
- ICG 0.24
- VNDA 0.20
- MACD
- ICG 0.06
- VNDA 0.02
- Stochastic Oscillator
- ICG 70.67
- VNDA 62.50
About ICG Intchains Group Limited
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.